NSCLC (Issue 4)

Vassiliki Papadimitrakopoulou, MD, from the University of Texas MD Anderson Cancer Center, discusses the implementation of personalized medicine for lung cancer patients.

Roy S. Herbst, MD, PhD, from Yale-New Haven in Connecticut, discusses the benefit of treating lung cancer with immunotherapy.

The Cancer Genome Atlas (TCGA) began in 2006, with a total investment of $100 million from the National Cancer Institute and the National Human Genome Research Institute for a 3-year pilot period.

Drs. Grace Dy and Hongbin Chen Discuss Systemic Treatment for Metastatic, Non-Small Cell Lung Cancer (NSCLC)

Fred R. Hirsch, MD, PhD, Professor of Medicine and Pathology, Associate Director for International Programs, University of Colorado Cancer Center, discusses the importance of biomarkers for lung cancer.

Immunotherapies have shown great promise in the treatment of advanced cancers, including metastatic melanoma and non-small cell lung cancers (NSCLC)

Oncogenic driver mutations have been detected in over 60% of the non-small cell lung cancer (NSCLC) tumor samples surveyed by the Lung Cancer Mutation Consortium (LCMC).

Therapeutic options available for the treatment of metastatic non-small cell lung cancer (NSCLC) include cytotoxic chemotherapies and targeted therapies.